Redeye raises its Base Case and forecasts for ADDvise following a strong Q4 and the recent letters of intent to acquire. Organic and acquired EBITDA growth was solid, and the order intake suggests continued momentum. The company is still trading at a substantial discount to its larger peers.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/